| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70571
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate |
2008-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57ff0695f2f519812e574c6f9ee52ed3 |
| publicationDate |
2009-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009124592-A1 |
| titleOfInvention |
Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity |
| abstract |
This invention relates to the use of a ligand of the 5-HT 4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT 4 receptor or of a functionally equivalent receptor for a drug for treating and/or preventing a pathology associated with an obsessional behavior such as anorexia, bulimia and the addiction to drugs of abuse or obesity. The invention also relates to a method for identifying a compound that is biologically active in the treatment and/or the prevention of a pathology associated with an obsessional conduct or obesity including: a) placing the 5-HT 4 receptor or a functionally equivalent receptor in contact with this biologically active compound, and b) the determination of whether this biologically active compound is capable of modulating the basal activity of the 5-HT 4 receptor or of a functionally equivalent receptor. |
| priorityDate |
2002-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |